MLH1 and neoplasm: A similar percentage can be calculated from data published by Hampel et al (2005): after exclusion of MSI-positive tumours with methylation of the MLH1 promoter, they found a germline mutation in 23 out of 29 patients (79%) with an MSI-positive tumour.